Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auto-FMT for CDI Prophylaxis in Allo-HSCT
NCT02269150Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in Clostridium difficile infection (CDI), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2014; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02269150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269150.